V5Z Stock Overview
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs in the United Sates, the People’s Republic of China, and Hong Kong.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sirnaomics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.59 |
| 52 Week High | HK$3.48 |
| 52 Week Low | HK$1.59 |
| Beta | -0.50 |
| 1 Month Change | 0% |
| 3 Month Change | -51.99% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| V5Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | 1.9% |
| 1Y | n/a | -25.4% | 5.9% |
Return vs Industry: Insufficient data to determine how V5Z performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how V5Z performed against the German Market.
Price Volatility
| V5Z volatility | |
|---|---|
| V5Z Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V5Z's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine V5Z's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 145 | Alan Patrick Lu | www.sirnaomics.com |
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs in the United Sates, the People’s Republic of China, and Hong Kong. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat remodeling. The company’s lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis.
Sirnaomics Ltd. Fundamentals Summary
| V5Z fundamental statistics | |
|---|---|
| Market cap | €74.81m |
| Earnings (TTM) | -€72.95m |
| Revenue (TTM) | €368.06k |
214.2x
P/S Ratio-1.1x
P/E RatioIs V5Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V5Z income statement (TTM) | |
|---|---|
| Revenue | US$397.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$397.00k |
| Other Expenses | US$79.09m |
| Earnings | -US$78.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 100.00% |
| Net Profit Margin | -19,821.41% |
| Debt/Equity Ratio | 125.3% |
How did V5Z perform over the long term?
See historical performance and comparison